Inventiva Reports Final Patient Visit In Phase 3 NATiV3 Study For Lanifibranor; Topline Data In Q4

Inventiva (IVA) announced the last patient visit in its Phase 3 NATiV3 trial of lanifibranor for MASH with moderate to advanced fibrosis. While no efficacy or timing for topline results was provided, completing enrollment/progressing to late-stage readouts is a constructive clinical milestone. Overall, the update modestly improves sentiment toward the program’s potential.